Trial
NCT02807454
A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma
Phase IITERMINATEDREGULATORYConfidence: HIGH
Sponsor
Celgene
Collaborators
—
Condition
Multiple Myeloma
Intervention
Daratumumab
Why stopped
Health Authority request due to class effect
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-02-21